Skip to content

Effect of Lung-Protective Ventilation During General Anesthesia on the Reduction of Complication Incidence and Airway Patency: A Randomized Controlled Trial

Effect of Lung-Protective Ventilation During General Anesthesia on the Reduction of Complication Incidence and Airway Patency: A Randomized Controlled Trial - Effect of Lung-Protective Ventilation During General Anesthesia on the Reduction of Complication Incidence and Airway Patency: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000061549
Enrollment
80
Registered
2026-05-13
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minor surgical conditions, primarily including superficial bladder cancer

Interventions

Lung-protective ventilation group (5 mL/kg) Conventional ventilation group (8 mL/kg)

Sponsors

Institute of Science Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Adults aged >=18 years at the time of consent. 2)Adult patients scheduled to undergo minor surgical procedures under general anesthesia managed with a supraglottic airway device. 3)Patients who have received a full explanation of the study, have adequately understood it, and have provided written informed consent voluntarily.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria: 1)Patients whose upper airway is managed with devices other than a supraglottic airway device. 2)Patients who have withdrawn consent and expressed refusal to participate in this study. 3)Patients with severe hepatic dysfunction. 4)Patients in whom succinylcholine is contraindicated. 5)Patients deemed unsuitable for the study by the principal investigator.

Design outcomes

Primary

MeasureTime frame
Incidence of capnography-detected abnormalities in end-tidal carbon dioxide waveforms immediately after neuromuscular blockade reversal under supraglottic airway device management

Secondary

MeasureTime frame
Glottic angle observed fiberoptically through a supraglottic airway device

Countries

Japan

Contacts

Public ContactKatsuhiko Ishibashi

Institute of Science Tokyo Hospital Anesthesiology

ishibashi.k.3dd4@m.isct.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026